- Home
- TOVX vs ENVB Comparison
TOVX vs ENVB Comparison
Compare TOVX & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- ENVB
- Stock Information
- Founded
- TOVX 2001
- ENVB 1994
- Country
- TOVX United States
- ENVB United States
- Employees
- TOVX N/A
- ENVB N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- ENVB Health Care
- Exchange
- TOVX Nasdaq
- ENVB Nasdaq
- Market Cap
- TOVX 3.5M
- ENVB 4.2M
- IPO Year
- TOVX 2006
- ENVB N/A
- Fundamental
- Price
- TOVX $1.21
- ENVB $0.35
- Analyst Decision
- TOVX Strong Buy
- ENVB Strong Buy
- Analyst Count
- TOVX 1
- ENVB 1
- Target Price
- TOVX $6.00
- ENVB $10.00
- AVG Volume (30 Days)
- TOVX 102.1K
- ENVB 156.7K
- Earning Date
- TOVX 11-12-2024
- ENVB 11-14-2024
- Dividend Yield
- TOVX N/A
- ENVB N/A
- EPS Growth
- TOVX N/A
- ENVB N/A
- EPS
- TOVX N/A
- ENVB N/A
- Revenue
- TOVX N/A
- ENVB N/A
- Revenue This Year
- TOVX N/A
- ENVB N/A
- Revenue Next Year
- TOVX N/A
- ENVB N/A
- P/E Ratio
- TOVX N/A
- ENVB N/A
- Revenue Growth
- TOVX N/A
- ENVB N/A
- 52 Week Low
- TOVX $1.14
- ENVB $0.30
- 52 Week High
- TOVX $17.00
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- TOVX 37.37
- ENVB 40.19
- Support Level
- TOVX $1.15
- ENVB $0.34
- Resistance Level
- TOVX $1.34
- ENVB $0.37
- Average True Range (ATR)
- TOVX 0.07
- ENVB 0.03
- MACD
- TOVX 0.01
- ENVB 0.01
- Stochastic Oscillator
- TOVX 7.41
- ENVB 53.66
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.